Sigma Planning Corp’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-7,224
Closed -$717K 1143
2019
Q3
$717K Sell
7,224
-871
-11% -$82.8K 0.03% 462
2019
Q2
$748K Sell
8,095
-4,328
-35% -$411K 0.04% 422
2019
Q1
$1.17M Sell
12,423
-19,852
-62% -$1.74M 0.07% 282
2018
Q4
$2.07M Buy
32,275
+268
+0.8% +$19.8K 0.15% 150
2018
Q3
$2.86M Buy
32,007
+15,655
+96% +$1.38M 0.17% 129
2018
Q2
$1.3M Buy
16,352
+3,984
+32% +$331K 0.09% 231
2018
Q1
$1.1M Buy
12,368
+1,950
+19% +$187K 0.08% 249
2017
Q4
$1.09M Sell
10,418
-9,416
-47% -$1.06M 0.08% 252
2017
Q3
$2.89M Buy
19,834
+15,866
+400% +$2.16M 0.24% 95
2017
Q2
$515K Sell
3,968
-846
-18% -$104K 0.05% 401
2017
Q1
$599K Buy
4,814
+723
+18% +$86.5K 0.06% 342
2016
Q4
$474K Buy
4,091
+826
+25% +$92K 0.05% 364
2016
Q3
$341K Sell
3,265
-202
-6% -$21.9K 0.04% 468
2016
Q2
$342K Buy
3,467
+235
+7% +$24.3K 0.04% 442
2016
Q1
$323K Sell
3,232
-682
-17% -$70.2K 0.04% 429
2015
Q4
$469K Sell
3,914
-261
-6% -$30.2K 0.07% 333
2015
Q3
$452K Buy
4,175
+829
+25% +$103K 0.07% 324
2015
Q2
$387K Buy
3,346
+1,108
+50% +$127K 0.05% 414
2015
Q1
$258K Sell
2,238
-238
-10% -$28.4K 0.03% 581
2014
Q4
$277K Buy
+2,476
New +$261K 0.04% 529

Other funds holding CELG

Sigma Planning Corp's CELG Position: Q4 2019 in Review

Sigma Planning Corp sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 7,224 shares — an estimated $717K sold.

Sigma Planning Corp first reported a position in CELG in Q4 2014 and held it in 20 quarters. The position peaked at $2.89M in Q3 2017. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Sigma Planning Corp reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Sigma Planning Corp sold 7,224 Celgene Corp shares in Q4 2019, an estimated $717K.
  • Sigma Planning Corp first reported a position in Celgene Corp in Q4 2014 and held it in 20 quarters.
  • Sigma Planning Corp's Celgene Corp position peaked at $2.89M in Q3 2017.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Sigma Planning Corp's 13F filing for Q4 2019, filed 3 Feb 2020.